- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
Olympic Drug Testing Lab to Become National Phenome Center
1 August 2012 11:01 am
LONDON—The Medical Research Council (MRC) and the National Institute for Health Research (NIHR), both funded by the U.K. government, have arranged to take over the Olympics antidoping laboratory. They plan to transform it into a national center dedicated to metabolic phenotyping, a field that examines blood, urine, and tissues for the thousands of molecules produced by the body's chemical reactions, with the aim of linking them up to diseases.
"There is nothing like this anywhere in the world," says Jeremy Nicholson, head of the surgery and cancer department at Imperial College London and a pioneer of the emerging field, who will become the center's first research director.
The state-of-the-art antidoping laboratory, the size of seven tennis courts, was originally a partnership between drug control scientists at King's College London and the British pharmaceutical firm GlaxoSmithKline. It was going to be closed at the end of the Olympics, says Jonathan Weber, research director for medicine at Imperial College London, who helped coordinate the proposal. The switchover to the MRC-NIHR Phenome Centre, as it will be known, is slated for early October, and the center will open for business in January.
A phenome describes all of a person's physiological traits in the same way that a genome describes genetic features; metabolic phenotyping focuses on metabolites, the products of chemical reactions inside the body. By studying these unique biochemical signatures in fluids such as blood and urine, it's possible to make connections between a person's metabolism and the diseases they develop, which may lead to diagnostic tests and drugs targeted to a person's individual biochemistry.
The antidoping lab has mass spectrometers and machines for high performance liquid chromatography and gas chromatography, allowing high-throughput testing of more than 6000 urine and blood samples from athletes. About 60% of this equipment will be reused.
MRC and NIHR are each providing £5 million of funding; the site and buildings belong to GlaxoSmithKline, while the U.S.-based equipment manufacturers Bruker BioSpin and Waters will provide instrumentation. The center will analyze about 25,000 samples in its first year, with the aim of scaling up to 100,000 a year.
More on this story in Friday's print edition of Science.